Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has shared an update.
Shandong Xinhua Pharmaceutical has received approval from China’s National Medical Products Administration confirming that its phenobarbital tablets have passed the national evaluation for consistency of quality and efficacy for generic drugs. The 30 mg prescription tablets, used to treat anxiety, insomnia, and epilepsy, are classified as a chemical drug and are included as a Category A product in the National Drug Catalogue for basic medical, work-related injury, and maternity insurance.
The approval follows an application submitted in May 2025 and formally accepted by the Center for Drug Evaluation, culminating in a supplemental drug application approval in May 2026. With phenobarbital tablets generating about RMB220 million in sales in China’s public medical institutions in 2025, the regulatory clearance strengthens Xinhua Pharmaceutical’s position in an important reimbursed central nervous system therapy segment and may reinforce its competitiveness in the domestic generics market.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a China-based pharmaceutical manufacturer focused on chemical prescription drugs. The company develops and produces generic medicines for use in public medical institutions and is listed in both mainland China and Hong Kong capital markets.
Average Trading Volume: 859,359
Technical Sentiment Signal: Hold
Current Market Cap: HK$9.47B
See more insights into 0719 stock on TipRanks’ Stock Analysis page.